Questions remain about safety of aspirin cessation in older adults

Questions remain about safety of aspirin cessation in older adults

A subgroup analysis of the ASPREE trial could not conclusively demonstrate clear harm or benefit of either cessation or continuation of aspirin in older adults who regularly use aspirin without a clinical indication for its use, according to a research letter published online March 15 in the Annals of Internal Medicine.

Mark R. Nelson, M.B.B.S., Ph.D., from the University of Tasmania in Hobart, and colleagues performed a post-hoc analysis of participants from the ASPREE trial to examine the effect of versus continuation among individuals aged 70 years or older who reported taking aspirin two or more days per week at trial enrollment. Participants were randomly assigned to either placebo (cessation) or aspirin (continuation). A composite of all-cause mortality, incident dementia, or persistent physical disability was assessed as the primary outcome.

The researchers found that 11 percent of the 19,114 recruited participants reported aspirin use before trial entry, and of these participants, 1,714 reported taking aspirin two or more days per week. During a median follow-up of 4.9 years, there was weak evidence of an increased risk for the primary outcome for aspirin cessation versus continuation; this finding seemed to be confined to non-White participants. The primary end point was experienced by 13.8 and 11.1 percent in the cessation and continuation groups, respectively (incidence rate, 28.8 versus 23.4 per 1,000 person years); the hazard ratio was 1.28 (95 percent confidence interval, 0.98 to 1.68). Among those taking aspirin for five years or longer, aspirin cessation appeared to increase cardiovascular disease events, although it was not associated with secondary end points.

"At this time, a pragmatic recommendation may be to consider aspirin cessation in those with a large medication burden with due caution," the authors write.

More information: Mark R. Nelson et al, Safety of Ceasing Aspirin Used Without a Clinical Indication After Age 70 Years: A Subgroup Analysis of the ASPREE Randomized Trial, Annals of Internal Medicine (2022). DOI: 10.7326/M21-3823

Ella Murphy et al, Does Stopping Aspirin Differ Fundamentally From Not Starting Aspirin in the Primary Prevention of Cardiovascular Disease Among Older Adults?, Annals of Internal Medicine (2022). DOI: 10.7326/M22-0550

Journal information: Annals of Internal Medicine

© 2022 HealthDay. All rights reserved.

Citation: Questions remain about safety of aspirin cessation in older adults (2022, March 15) retrieved 25 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Aspirin use doesn't cut cancer incidence in older T2DM patients


Feedback to editors